From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38251977.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3571.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Primary and secondary brain tumors cause significant mortality and constitute an important unmet need. The development of AZD9574, a brain-penetrant, PARP1-selective inhibitor with favorable pharmacologic properties and intriguing preclinical activity, has led to an ongoing clinical trial evaluating it alone and in combination with temozolomide or antibody drug conjugates. See related article by Staniszewska et al., p. 1338.
Medical subject headings
- Brain
- Brain Neoplasms